Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 11, 2009
Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population
Paul Tappenden, Christopher McCabe, Jim Chilcott, et al.
Clinical Therapeutics
|
September 23, 2008
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
BMJ (Clinical Research Ed.)
|
March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis
Jim Chilcott, Chris McCabe, Paul Tappenden, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
January 23, 2009
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
British Journal of Cancer
|
January 15, 2016
Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm
Benjamin Kearns, Sophie Whyte, Helen E Seaman, et al.
BMJ Open
|
September 7, 2023
Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk
James Wf Catto, Bernard North, Megan Goff, et al.
Bioanalysis
|
December 20, 2019
Effect of blood volume on analytical bias in dried blood spots prepared for newborn screening external quality assurance
Stuart J Moat, Catherine Dibden, Lesley Tetlow, et al.
BMJ Public Health
|
February 28, 2025
Relationship of cardiorenal risk factors with albuminuria based on age, smoking, glycaemic status and BMI: a retrospective cohort study of the UK Biobank data
Debasish Kar, Aya El-Wazir, Mintu Nath, et al.
BJU International
|
January 21, 2023
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019
James W F Catto, Olena Mandrik, Lewis A Quayle, et al.
International Journal of Neonatal Screening
|
October 24, 2025
Methodological and Procedural Considerations for Developing Decision Analytic Models to Assess the Health Economic Impacts of Newborn Bloodspot Screening: A Systematic Methodological Review
Jim Chilcott, Alice Bessey, James R Bonham, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 11, 2009
Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population
Paul Tappenden, Christopher McCabe, Jim Chilcott, et al.
Clinical Therapeutics
|
September 23, 2008
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
BMJ (Clinical Research Ed.)
|
March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis
Jim Chilcott, Chris McCabe, Paul Tappenden, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
January 23, 2009
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
British Journal of Cancer
|
January 15, 2016
Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm
Benjamin Kearns, Sophie Whyte, Helen E Seaman, et al.
BMJ Open
|
September 7, 2023
Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk
James Wf Catto, Bernard North, Megan Goff, et al.
Bioanalysis
|
December 20, 2019
Effect of blood volume on analytical bias in dried blood spots prepared for newborn screening external quality assurance
Stuart J Moat, Catherine Dibden, Lesley Tetlow, et al.
BMJ Public Health
|
February 28, 2025
Relationship of cardiorenal risk factors with albuminuria based on age, smoking, glycaemic status and BMI: a retrospective cohort study of the UK Biobank data
Debasish Kar, Aya El-Wazir, Mintu Nath, et al.
BJU International
|
January 21, 2023
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019
James W F Catto, Olena Mandrik, Lewis A Quayle, et al.
International Journal of Neonatal Screening
|
October 24, 2025
Methodological and Procedural Considerations for Developing Decision Analytic Models to Assess the Health Economic Impacts of Newborn Bloodspot Screening: A Systematic Methodological Review
Jim Chilcott, Alice Bessey, James R Bonham, et al.
Page
of 4